David L. DeRemer

Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression<i>in vitro</i>and<i>in vivo</i>

Anna Goc, Belal Al‐Husein, Katerina Katsanevas et al. · Oncotarget · 2014 · 74 citations · Full text

Medicine, Oncology, Pharmacology +17

Intermediate-Dose versus Low-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Therapies

Mehdi Hamadani, Samith T. Kochuparambil, Salman Osman et al. · Biology of Blood and Marrow Transplantation · 2012 · 72 citations · Full text

Medicine, Hematology, Pharmacotherapy +15

The Importance of Research and Scholarly Activity in Pharmacy Training

Eli N. Deal, Paul M. Stranges, Whitney D. Maxwell et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2016 · 72 citations

Pharmacy, Pharmacy Practice, Pharmacy Administration +12

Adverse Cardiovascular Events Associated With Cyclin‐Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer

Michael G. Fradley, Nam Nguyen, David Madnick et al. · Journal of the American Heart Association · 2023 · 56 citations · Full text

Medicine, Oncology, Pharmacology +14

Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial

Amber B. Clemmons, Julianne Orr, Benjamin Andrick et al. · Biology of Blood and Marrow Transplantation · 2018 · 55 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17